Karyopharm CEO sells 12,361 shares for tax withholding

Karyopharm Therapeutics Inc. President and CEO Richard A. Paulson reported an automatic sale of common stock under a pre-established durable automatic sale instruction plan.

Accepted by SEC EDGAR 03/03/2026 - 04:21 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. President and CEO Richard A. Paulson reported an automatic sale of common stock under a pre-established durable automatic sale instruction plan. On this transaction date, he sold 12,361 shares of common stock at an average price of $9.4095 per share in a broker-assisted transaction to satisfy withholding tax obligations arising from the vesting of restricted stock units. Following this tax-related, non-discretionary sale, he continued to hold 267,030 shares of Karyopharm Therapeutics common stock directly.

Insider Trade Summary

Net Seller: 12,361 shares

Net Sell 1 txn

Insider Paulson Richard A.

Role President and CEO

Sold 12,361 shs ($116K)

Share of Position Sold 4.4%

Type	Security	Shares	Price	Value
Sale	Common Stock	12,361	$9.4095	$116K

Holdings After Transaction: Common Stock — 267,030 shares (Direct)

Holdings Before and After: Common Stock, 279,391 to 267,030 shares (Direct)

Other Insiders: 6 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Karyopharm Therapeutics (KPTI) CEO Richard Paulson report in this Form 4?

Richard Paulson reported an automatic sale of 12,361 Karyopharm Therapeutics common shares. The broker-assisted sale was executed under a durable automatic sale instruction plan and was used to cover withholding taxes from vesting restricted stock units, rather than a discretionary open-market trade.

How many Karyopharm Therapeutics (KPTI) shares did the CEO sell and at what price?

The CEO sold 12,361 shares of Karyopharm Therapeutics common stock at an average price of $9.4095 per share. This transaction was executed by a broker to satisfy tax withholding obligations triggered by restricted stock unit vesting.

Why were Karyopharm Therapeutics (KPTI) shares sold in this insider transaction?

The shares were sold to satisfy withholding tax liability incurred when restricted stock units vested. According to the disclosure, the sale occurred under a durable automatic sale instruction plan and did not represent a discretionary trading decision by the reporting person.

Does Karyopharm Therapeutics (KPTI) CEO Richard Paulson still hold shares after this Form 4 sale?

Yes. After the tax-related sale of 12,361 shares, Richard Paulson directly held 267,030 shares of Karyopharm Therapeutics common stock. The filing shows the remaining ownership position following the transaction reported in this Form 4.

Was the Karyopharm Therapeutics (KPTI) insider trade part of a planned program?

Yes. The transaction was executed pursuant to a durable automatic sale instruction plan adopted on June 10, 2021. The filing states the sale was broker-assisted, used for tax withholding, and did not constitute a discretionary trade by the CEO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Paulson Richard A.

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MA 02459

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S(1)		12,361	D	$9.4095	267,030	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

	/s/ Nancy Smith as Attorney-in-Fact for Richard Paulson	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.